The first test phase of a vaccine against zika, developed by two Franco-Austrian and US groups, was positive, according to a statement released Monday. The product has been shown to be immunogenic on all groups tested.
The Franco-Austrian group Valneva and the American Emergent BioSolutions announced Monday "positive preliminary results"for Phase I of their Zika vaccine candidate The vaccine candidate called VLA1601 has"achieved the primary endpoint of the study by showing a favorable safety profile for all doses and vaccination regimens tested", said the two groups in a joint statement.
Proven antibody production
VLA1601 has, moreover, "demonstrated to be immunogenic (antibody production) in all vaccinated groups and generated antibodies against Zika virus based on doses and vaccination schedules", they added.The Phase I study"evaluates the safety and immunogenicity of two different assays of the inactivated and adjuvanted alum vaccine candidate in 67 healthy adults not previously infected with flavivirus, aged 18-49 years", they said.
End of co-development
In July 2017, Valneva granted an exclusive worldwide license to Emergent BioSolutions for its zika vaccine production technology. The two companies had agreed to co-develop the vaccine until the release of Phase I data, with Valneva responsible for the operations.
For its part, Emergent has an option to continue the development of the vaccine once the Phase I results are obtained.
In exchange, the American had committed to pay a first milestone payment of 5 million euros and "additional milestone payments related to clinical product development, marketing and commercialization, up to 44 million euros".
View the Valneva and Emergent BioSolutions joint press release: